Domestic new drug development bio companies are shifting to a full-fledged profit-generating structure through technology exports and sales of their own new drugs. Unlike in the past, when prolonged losses after listing were the norm, there have recently been a series of cases in which companies post profits in the first year of listing or renew their all-time high performance. The assessment is that the bio industry, once regarded as a research and development-centered sector, is moving into a stage where it generates tangible profits.


The quality of earnings is also improving as technology transfer up-front payments, milestone revenues, and sales of proprietary new drugs are reflected simultaneously. Analysts say a virtuous cycle is beginning to take root, in which research achievements translate into cash flow, and this capital is reinvested into subsequent pipelines. However, some point out that going forward it will be necessary to evolve beyond simple technology transfer into cooperative models that share development risks and know-how with global pharmaceutical companies.

New Drug Success Driving Earnings... Korean Bio Firms Enter Profit-Generation Phase View original image

Meanwhile, interest in stock loans is growing by the day. Investors who do not want to miss rare investment opportunities are turning their attention to stock loans, which allow them to use more funds to purchase stocks.


In addition, even if investors using margin or credit trading face a forced liquidation crisis due to a sharp stock price drop, one of the advantages of stock loans is that they can simply switch over without providing additional collateral or selling holdings, and then wait for a rebound.


◆ All New Stock Loan, from products with the lowest interest rates in the 5% per annum range to products exempt from DSR!

All New Stock Loan has launched a securities-linked credit product with the industry’s lowest interest rate in the 5% per annum range so that any investor can use stock loans without burden. It can be used not only for stock purchases but also for refinancing margin or credit balances at securities firms, and up to four times the investor’s own capital can be utilized regardless of credit rating.


At the same time, it also offers a DSR-free product for investors who previously found it difficult to use stock loans due to DSR limits. Investors using the alternative trading system (NXT) can also take advantage of this service.


Investors who want to know more about All New Stock Loan can contact the customer service center (☎1599-8666) and conveniently consult with a professional counselor at any time, regardless of whether they ultimately take out a loan.


○ Launch of a product with the industry’s lowest interest rate in the 5% per annum range!

○ Regardless of existing loan balance or income! (DSR not applied)

○ Ability to use up to four times the amount of stock investment funds! (including own capital)

○ Same-day instant refinancing of securities credit/margin balances available!

○ Trading on the alternative trading system (NXT) available

○ Even stocks that were difficult to buy using existing securities firm credit or stock loans are OK!

* All New Stock Loan Customer Service Center: 1599-8666

Go directly: https://allnewstockloan.co.kr?agency=HTS


Wonik IPS, Alteogen, Hanwha Ocean, Ecopro BM, Hanwha Systems



※ The above content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing